Leonardo is living with type 1 diabetes in Mexico, studying in high school and doing triathlons.

Annual report 2020

Novo Nordisk at a glance

Novo Nordisk is a global healthcare company, headquartered in Denmark. 

Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world. We aim to lead in all disease areas in which we are active.

Facts & figures

126,946

DKK million in net sales

54,126

DKK million in operating profit 

45,323

employees worldwide

169

countries with marketed products 

Our corporate strategy

Our corporate strategy has four distinct focus areas in which we operate. It is build on our purpose, the Novo Nordisk Way and our ambition to be a sustainable business. We aim to strengthen our treatment options in diabetes and obesity care, secure leading positions within rare blood and endocrine disorders, and establish a strong presence in other serious chronic diseases such as NASH, cardiovascular disease and Alzheimer’s disease, and provide curative therapies based on our stem cell platform. Succeeding in this will ensure diversified sources of growth to drive sustainable growth for Novo Nordisk.

Diseases areas

463

million people live with diabetes

650

million people live with obesity

450

thousand people live with haemophilia